We use cookies for a better user experience. Read our Privacy Policy
I Agree
Post-operative Nausea and Vomiting (PONV) Market
Post-operative Nausea and Vomiting (PONV) Market - Snapshot
The global post-operative nausea and vomiting (PONV) market is growing at a significant rate due to bourgeoning incidence rate of post-operative complications and increasing demand for combination therapy, as well as introduction of promising drugs in this segment across the globe. The global PONV market was valued at US$ 1,608.6 Mn in 2017. It is projected to register a compound annual growth rate (CAGR) of 8.1% from 2018 to 2026 to reach a value of the US$ 3,174.1 Mn by 2026. The market is witnessing a relatively moderate growth owing to increase in patient population experiencing post-operative nausea and vomiting and rise in the rate of adoption of combination therapies as well as non-pharmacological treatment modes globally.
According to treatment guidelines, the suggested pharmacologic anti-emetics for prophylaxis of PONV in adults include serotonin antagonists; such as, ramosetron, granisetron, palonosetron, ondansetron, dolasetron, and tropisetron, neurokinin-1 (NK-1) receptor antagonists; such as aprepitant, and rolapitant, steroids; such as dexamethasone and methylprednisolone, dopamine antagonists as transdermal scopolamine [TDS] and others; such as butyrophenones as well as antihistamines (dimenhydrinate and meclizine). Postoperative nausea and vomiting is considered a major clinical issue that can diminish a patient’s quality of life. Additionally, PONV leads to an increase in perioperative costs as well as morbidity, lengthens stay at the post-anesthesia care unit, increases hospital stay, delays the time taken by the patient to go back to work, and results in readmissions. Irrespective of the availability of multiple tools to segment patients as per PONV development risk criteria and treatment guidelines, physicians are unable to methodically address prophylaxis or treatment of PONV in a uniform manner through pharmacologic or non-pharmacologic strategies.
Major factors boosting the growth of the post-operative nausea and vomiting market include large number of surgeries performed and rise in the rate of postoperative complications, such as, dizziness, vomiting, and nausea. However, strict regulatory approvals and high health care expenditure are predicted to hamper the growth of the PONV market during the forecast period.
The global post-operative nausea and vomiting (PONV) market has been divided into three segments based on treatment type, distribution pattern, and geography. In terms of treatment type, the PONV market has been segmented into serotonin antagonists, steroids, dopamine antagonists, NK-1 receptor antagonists, others, and non-pharmacological treatment. Serotonin antagonist is expected to command the dominant share of the market owing to its proven safety profile and effectiveness, as well as for being physicians’ first preference drug in the management of post-operative nausea and vomiting. The non-pharmacologic treatment segment is expected to expand at a CAGR of 7.6% by 2026, owing to cost-effectiveness of the methods, such as, acupuncture, acupressure, and electrical acustimulation in the treatment of post-operative nausea and vomiting.
In terms of distribution pattern, the global post-operative nausea and vomiting (PONV) market has been classified into hospital pharmacies, online pharmacies, and retail pharmacies and online stores. The hospital pharmacies segment constitutes a major share of the PONV market owing to rising investment in the hospital sector, particularly in emerging countries, which is boosting the number of hospitals in these countries. This, in turn, is anticipated to increase the number of hospital pharmacies, thus improving accessibility to medications used in the treatment of PONV.
Geographically, the post-operative nausea and vomiting (PONV) market has been categorized into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the leading share of the global PONV market in 2017, followed by Europe, with a substantial market share. Presence of a large base of surgical patients as well as readiness among patients to pay extra money in order to avoid post-operative complications are expected to propel the PONV market in North America during the forecast period. Europe commands the second leading share of the global post-operative nausea and vomiting (PONV) market. High incidence rate of PONV among surgical patients in Europe and rise in R&D expenditure in pharmaceuticals are projected to lead to a large market size of the region.
Leading players operating in the global post-operative nausea and vomiting (PONV) market include Acacia Pharma, F. Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc., Camurus AB, Sanofi S.A., Helsinn Holding S.A., Eisai Corporation, Merck and Co., and GlaxoSmithKline Corporation.
The global PONV market has been segmented as follows:
|
Treatment |
|
|
Application |
|
|
Region |
|
The global post-operative nausea and vomiting (PONV) market was worth US$ 1,608.6 Mn and is projected to reach a value of US$ 3,174.1 Mn by the end of 2026
Post-operative nausea and vomiting (PONV) market is anticipated to grow at a CAGR of 8.1% during the forecast period
North America accounted for a major share of the global post-operative nausea and vomiting (PONV) market
The growth of the post-operative nausea and vomiting market include large number of surgeries performed and rise in the rate of postoperative complications, such as, dizziness, vomiting, and nausea
Key players in the global post-operative nausea and vomiting (PONV) market include Acacia Pharma, F. Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc., Camurus AB, Sanofi S.A., Helsinn Holding S.A., Eisai Corporation, Merck and Co., and GlaxoSmithKline Corporation
Chapter 1 Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Chapter 2 Assumptions and Research Methodology
Chapter 3 Executive Summary: Global Post-operative Nausea and Vomiting (PONV) Market
Chapter 4 Market Overview
4.1. Introduction
4.2. Key Industry Developments
Chapter 5 Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities
5.4. Trends
5.5. Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, 2016–2026
5.6. Global Post-operative Nausea and Vomiting (PONV) Market Outlook
Chapter 6 Market Outlook
6.1. Absolute Surgical Procedure Volume, by Region
6.2. Incidence of Post-operative Nausea and Vomiting, by Region, (2017 - Estimated)
6.3. Post-operative Nausea and Vomiting (PONV) Market: Pipeline Analysis
Chapter 7 Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Treatment Type
7.1. Key Findings
7.2. Introduction
7.3. Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
7.3.1. Serotonin Antagonists
7.3.2. Steroids
7.3.3. Dopamine Antagonists
7.3.4. NK-1 receptor Antagonists
7.3.5. Non-Pharmacologic Treatment
7.4. Market Attractiveness Analysis, by Treatment Type
Chapter 8 Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Distribution Channel
8.1. Key Findings
8.2. Global PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
8.2.1. Hospital Pharmacies
8.2.2. Online Pharmacies
8.2.3. Retail Pharmacies and Drug Stores
8.3. Global PONV Market Attractiveness Analysis, by Distribution Channel
8.4. Key Trends
Chapter 9 Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Market Scenario
9.3. Global PONV Market Value (US$ Mn) Forecast, by Region, 2018–2026
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Global PONV Market Attractiveness Analysis, by Region
Chapter 10 North America Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
10.1. Key Findings
10.2. North America PONV Market Size (US$ Mn) Forecast, by Country, 2018–2026
10.2.1. U.S.
10.2.2. Canada
10.3. North America PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
10.3.1. Serotonin Antagonists
10.3.2. Steroids
10.3.3. Dopamine Antagonists
10.3.4. NK-1 receptor Antagonists
10.3.5. Non-pharmacologic Treatment
10.4. North America PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
10.4.1. Hospital Pharmacies
10.4.2. Online Pharmacies
10.4.3. Retail Pharmacies and Drug Stores
10.5. North America PONV Market Attractiveness Analysis
10.5.1. By Country
10.5.2. By Treatment Type
10.5.3. By Distribution Channel
Chapter 11 Europe Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
11.1. Key Findings
11.2. Europe PONV Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
11.2.1. Germany
11.2.2. U.K.
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Europe PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
11.3.1. Serotonin Antagonists
11.3.2. Steroids
11.3.3. Dopamine Antagonists
11.3.4. NK-1 receptor Antagonists
11.3.5. Non-Pharmacologic Treatment
11.4. Europe PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
11.4.1. Hospital Pharmacies
11.4.2. Online Pharmacies
11.4.3. Retail Pharmacies and Drug Stores
11.5. Europe PONV Market Attractiveness Analysis
11.5.1. By Country
11.5.2. By Treatment Type
11.5.3. By Distribution Channel
Chapter 12 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
12.1. Key Findings / Developments
12.2. Market Overview
12.3. Asia Pacific PONV Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
12.3.1. China
12.3.2. India
12.3.3. Japan
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Asia Pacific PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
12.4.1. Serotonin Antagonists
12.4.2. Steroids
12.4.3. Dopamine Antagonists
12.4.4. NK-1 receptor Antagonists
12.4.5. Non-Pharmacologic Treatment
12.5. Asia Pacific PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
12.5.1. Hospital Pharmacies
12.5.2. Online Pharmacies
12.5.3. Retail Pharmacies and Drug Stores
12.6. Asia Pacific PONV Market Attractiveness Analysis
12.6.1. By Country
12.6.2. By Treatment Type
12.6.3. By Distribution Channel
Chapter 13 Latin America Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
13.1. Key Findings / Developments
13.2. Market Overview
13.3. Latin America PONV Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Latin America PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
13.4.1. Serotonin Antagonists
13.4.2. Steroids
13.4.3. Dopamine Antagonists
13.4.4. NK-1 receptor Antagonists
13.4.5. Non-Pharmacologic Treatment
13.5. Latin America PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
13.5.1. Hospital Pharmacies
13.5.2. Online Pharmacies
13.5.3. Retail Pharmacies and Drug Stores
13.6. Latin America PONV Market Attractiveness Analysis
13.6.1. By Country
13.6.2. By Treatment Type
13.6.3. By Distribution Channel
Chapter 14 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
14.1. Key Findings / Developments
14.2. Market Overview
14.3. Middle East & Africa PONV Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Israel
14.3.4. Rest of Middle East & Africa
14.4. Middle East & Africa PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
14.4.1. Serotonin Antagonists
14.4.2. Steroids
14.4.3. Dopamine Antagonists
14.4.4. NK-1 receptor Antagonists
14.4.5. Non-Pharmacologic Treatment
14.5. Middle East & Africa PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
14.5.1. Hospital Pharmacies
14.5.2. Online Pharmacies
14.5.3. Retail Pharmacies and Drug Stores
14.6. Middle East & Africa PONV Market Attractiveness Analysis
14.6.1. By Country
14.6.2. By Treatment Type
14.6.3. By Distribution Channel
Chapter 15 Competition Landscape
15.1. Global Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Key Players and Their Competitive Positioning
15.3. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
15.3.1. Acacia Pharma
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Strategic Overview
15.3.2. F. Hoffmann La Roche Ltd.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Strategic Overview
15.3.3. ANI Pharmaceuticals
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Sanofi
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. GlaxoSmithKline Corporation
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Eisai Co., Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Merck KGaA
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Novartis AG
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Helsinn Holding Co.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Camurus AB
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
List of Tables:
Table 01 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 02 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 03 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Region, 2016–2026
Table 04 North America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Country, 2016–2026
Table 05 North America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 06 North America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 07 Europe Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 08 Europe Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 09 Europe Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 10 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 11 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 12 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 13 Latin America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 14 Latin America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 15 Latin America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 16 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 17 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 18 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
List of Figures:
Figure 01 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn), by Distribution Channel, 2017
Figure 02 Global Post-operative Nausea and Vomiting (PONV) Market Size, by Treatment Type (US$ Mn), 2017
Figure 03 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn), by Region, 2017 and 2026
Figure 04 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, 2016–2026
Figure 05 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, 2016–2026
Figure 06 Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2017 and 2026
Figure 07 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Serotonin Antagonists, 2016–2026
Figure 08 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Steroids, 2016–2026
Figure 09 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Dopamine Antagonists, 2016–2026
Figure 10 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by NK1 Receptor Antagonists, 2016–2026
Figure 11 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Others, 2016–2026
Figure 12 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Non-pharmacologic Treatment, 2016–2026
Figure 13 Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type
Figure 14 Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel
Figure 15 Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Distribution Channel, 2018–2026
Figure 16 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Hospital Pharmacies, 2016–2026
Figure 17 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Online Pharmacies, 2016–2026
Figure 18 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Retail Pharmacies and Drug Stores, 2016–2026
Figure 19 Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Region, 2016 and 2025
Figure 20 Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Region
Figure 21 North America Post-operative Nausea and Vomiting (PONV) Market Value Share, by Country, 2017 and 2026
Figure 22 North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Country, 2018–2026
Figure 23 North America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment
Figure 24 North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Treatment, 2018–2026
Figure 25 North America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel
Figure 26 North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Distribution Channel, 2018–2026
Figure 27 Europe Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 28 Europe Post-operative Nausea and Vomiting (PONV) Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 29 Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 30 Europe Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment
Figure 31 Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Treatment, 2018–2026
Figure 32 Europe Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel
Figure 33 Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Distribution Channel, 2018–2026
Figure 34 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 35 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 36 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 37 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment
Figure 38 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Treatment, 2018–2026
Figure 39 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel
Figure 40 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Distribution Channel, 2018–2026
Figure 41 Latin America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 42 Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 43 Latin America Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 44 Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment
Figure 45 Latin America Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Treatment, 2018–2026
Figure 46 Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel
Figure 47 Latin America Postoperative Nausea and Vomiting (PONV) Market Attractiveness, by Distribution Channel, 2018–2026
Figure 48 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 49 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 50 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 51 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment
Figure 52 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Treatment, 2018–2026
Figure 53 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel
Figure 54 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Distribution Channel, 2018–2026
Figure 55 Acacia Pharma Research & Development Cost, 2015 – 2017 (US$ Mn)
Figure 56 F. Hoffmann-La Roche Ltd Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 57 F. Hoffmann-La Roche Ltd Breakdown of Net Sales, by Region, 2017
Figure 58 F. Hoffmann-La Roche Ltd Breakdown of Net Sales, by Business Segment, 2017
Figure 59 F. Hoffmann-La Roche Ltd Research & Development Cost, 2015 - 2017 (US$ Mn)
Figure 60 Novartis AG Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
Figure 61 Novartis AG Breakdown of Net Sales, by Region, 2017
Figure 62 Novartis AG Breakdown of Net Sales, by Business Segment, 2017
Figure 63 Novartis AG Breakdown of Net Sales, by Innovative Medicines Business Units, 2017
Figure 64 ANI Pharmaceuticals Inc. Research & Development Cost, 2015 - 2017 (US$ Mn)
Figure 65 ANI Pharmaceuticals Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
Figure 66 Camurus AB Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 67 Camurus AB Breakdown of Net Sales, by Region, 2017
Figure 68 Camurus AB Breakdown of Net Sales, by Business Segment, 2017
Figure 69 Camurus AB Research & Development Cost (US$ Mn), 2016–2017
Figure 70 Sanofi Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 71 Sanofi Breakdown of Net Sales, by Region, 2017
Figure 72 Sanofi Breakdown of Net Sales, by Business Segment, 2017
Figure 73 Sanofi Breakdown of Net Sales, by Pharmaceuticals, 2017
Figure 74 Eisai Inc. Breakdown of Net Sales, by Region, 2017
Figure 75 Eisai Inc. R&D Intensity Company Level (US$ Mn), 2016–2017
Figure 76 Eisai Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
Figure 77 Helsinn Healthcare S.A. Breakdown of Net Sales, by Region, 2016 (%)
Figure 78 Helsinn Healthcare S.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2016
Figure 79 Merck Group, Revenue (US$ Mn), 2015-2017
Figure 80 EMEND Revenue (US$ Mn), 2015-2017
Figure 81 EMEND Revenue, by Region (%), 2017
Figure 82 GSK’s Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2017
Figure 83 R&D Expenditure (US$ Mn), GSK Group, 2015-2017
Figure 84 Breakdown of GSK’s Vaccines Segment Net Sales, by Region, 2017
Figure 85 Breakdown of GSK’s Net Sales, by Business Segment, 2017
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes